Cellomatics has been named a finalist for Bioscience Innovator of the Year at the prestigious Go Global Awards 2025, which will be held in November 18–19, 2025, at One Great George Street, Westminster, London. This nomination recognises the company’s excellence in delivering innovative, high-quality, and data-driven solutions that accelerate pharmaceutical research worldwide.
Founded in 2015 and headquartered in Nottingham, United Kingdom, Cellomatics provides bespoke complex and translational cell-based assay services that enable biotech and pharmaceutical companies to de-risk decision-making and speed up R&D programmes. The company’s expertise spans immuno-inflammation, respiratory, oncology and immuno-oncology therapeutic areas, leveraging advanced human in vitro models to generate actionable insights that drive scientific and clinical progress.
With a talented team of scientists and professionals, Cellomatics has established itself as a trusted partner through its client-centric, collaborative approach. By combining deep expertise in cell biology with cutting-edge research techniques, the company empowers its partners to translate groundbreaking science into real-world therapies more efficiently.
“Cellomatics stands out in its pioneering approach to drug discovery and development. Their dedication to leveraging advanced in vitro models to deliver high-quality insights is truly commendable. It’s companies like Cellomatics that are driving innovation and excellence in the biosciences industry,” said Ranjani Rangan, Director of the International Trade Council.
The Bioscience Innovator of the Year award category is particularly relevant to Cellomatics as it underscores the company’s commitment to innovation within the life-sciences field. By offering tailored assay services and leveraging cutting-edge in vitro models, Cellomatics helps de-risk decision-making processes for its clients, thus facilitating faster and more effective drug development. This recognition by the Go Global Awards highlights the company’s role in advancing the biosciences industry through innovative practices and a client-centric approach.
Shailendra Singh, Cellomatics’ CEO and Founder, will represent the company at the Go Global Awards. Under his leadership, Cellomatics continues to advance preclinical research and strengthen its role in driving innovation across the global life sciences sector. Shailendra comments: “Being named a finalist for the Bioscience Innovator of the Year is an incredible honour for our team. This recognition is a testament to our dedication to providing innovative solutions that support our clients in their drug discovery efforts. We are excited about the opportunities this brings and look forward to continuing our contribution to the field of biosciences.”
This nomination underscores Cellomatics’ commitment to accelerating therapeutic innovation, improving global healthcare, and supporting transformative drug development.
Find out more about the awards here.
